Physician profile
Caitlin Pellant
NPI 1568010478
$1,667.50
in general payments reported to CMS, 2019-2025
11 companies · $585 in 2025
The $585 reported for 2025 was more than what 79% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $490 · 2024: $592 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.55 |
| Education | $187.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $247.39 | 2023-2024 | Welireg, Keytruda |
| Abbvie INC. | $223.94 | 2024-2025 | |
| American Regent | $195.24 | 2025 | Injectafer |
| Beigene USA, INC. | $169.30 | 2023-2025 | Brukinsa |
| Genentech USA, INC. | $148.17 | 2023 | Polivy, Columvi |
| Pharmacosmos Therapeutics INC. | $146.15 | 2024 | Monoferric |
| Daiichi Sankyo INC. | $123.56 | 2025 | Vanflyta |
| Emd Serono, INC. | $118.72 | 2024 | |
| Agios Pharmaceuticals, INC. | $107.08 | 2025 | Pyrukynd |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Incyte Corporation | $89.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Pellant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.